ArticleNature2021
Inter-cellular CRISPR screens reveal regulators of cancer cell phagocytosis.
Open access · greenAbstract read
In one paragraph
Article in Nature, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 120 papers.
0numbers the graph read from it
0cells of the map it votes in
120citing papers in PubMed
11.0field-weighted citation impact, top 1% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
120 citing papers in PubMed, 179 citations in OpenAlex.
- Metabolic immune checkpoints (MICs) in cancer: from molecular mechanisms to challenges and opportunities in clinical translation.Signal transduction and targeted therapy · 2026Review
- CRISPR in clinical oncology: translational advances from molecular diagnostics to therapeutics.Nature reviews. Clinical oncology · 2026Review
- Mechanism of GPR84 allosteric modulation at a helix 8-proximate site.Science advances · 2026Article
- Protocol for robust gene knockout and reliable validation in human cell lines using quad-guide RNA vectors.STAR protocols · 2026Article
- Steric control of signaling bias in the immunometabolic receptor GPR84.Nature communications · 2026Article
- High-Content CRISPR Screening: Methods and Applications.MedComm · 2026Review
- Virus-like particles enable targeted gene engineering and pooled CRISPR screening in primary human myeloid cells.Nature biotechnology · 2026Article
- Surfaceome CRISPR activation screening uncovers ligands regulating tumor sensitivity to NK cell killing.Nature communications · 2026Article
- Myeloid cell-mediated killing of B-ALL by CD38 and CD20 IgA antibody variants is enhanced by CD47/SIRPα interference.Blood neoplasia · 2026Article
- IQGAP2 regulates phagocytic-like activity and PD-L1 expression in glioma through the JAK2/STAT3 axis.Molecular biology reports · 2026Article
- Multi-omics identification of an antibody dependent cellular phagocytosis related signature for hepatocellular carcinoma.Translational cancer research · 2026Article
- Regulatory patterns of antibody-dependent cellular phagocytosis-related genes in triple-negative breast cancer: An integrated multi-omics and single-cell analysis.Naunyn-Schmiedeberg's archives of pharmacology · 2026Article
- Macrophages: Targets for next-generation cancer immunotherapy.Cancer cell · 2026Review
- Targeting phagocytosis checkpoints for cancer immunotherapy.Nature reviews. Cancer · 2026Review
- Fatty Acid-Sensing G Protein-Coupled Receptors in Skeletal Metabolism.Journal of bone metabolism · 2026Article
- Targeting metabolic-epigenetic-immune axis in cancer: molecular mechanisms and therapeutic implications.Signal transduction and targeted therapy · 2026Review
- APMAP regulated by YY1 transcription mediates ferroptosis and metastasis in non-small cell lung cancer through the PI3K/AKT/mTOR pathway.Journal of molecular histology · 2026Article
- Splenic cDC1 efferocytosis and cross-presentation to CD8 T cells are promoted by GPR34 and lysophosphatidylserine.The Journal of experimental medicine · 2026Article
- Case Report: Post-mortem analysis of long-term inflammation after mild COVID-19.Frontiers in immunology · 2026Article
- High-throughput screening to engineer optimal T cell therapies: current knowledge and future prospects.Frontiers in oncology · 2026Review
60 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
18 authors at 3 institutions in 1 country.
Roarke A KamberDepartment of Genetics, Stanford University School of Medicine, Stanford, CA, USA.
Yoko NishigaDepartment of Genetics, Stanford University School of Medicine, Stanford, CA, USA.
Bhek MortonDepartment of Genetics, Stanford University School of Medicine, Stanford, CA, USA.
Allison M BanuelosInstitute for Stem Cell Biology and Regenerative Medicine, Stanford University School of Medicine, Stanford, CA, USA.
Amira A BarkalInstitute for Stem Cell Biology and Regenerative Medicine, Stanford University School of Medicine, Stanford, CA, USA.
Felipe Vences-CatalánDivision of Oncology, Department of Medicine, Stanford University School of Medicine, Stanford, CA, USA.
Mingxin GuDepartment of Genetics, Stanford University School of Medicine, Stanford, CA, USA.
Daniel FernandezProgram in Chemistry, Engineering, and Medicine for Human Health (ChEM-H), Stanford University, Stanford, CA, USA.ORCID http://orcid.org/0000-0002-6221-152X
Jose A SeoaneStanford Cancer Institute, Stanford University School of Medicine, Stanford, CA, USA.ORCID http://orcid.org/0000-0002-3856-9177
David YaoDepartment of Genetics, Stanford University School of Medicine, Stanford, CA, USA.
Katherine LiuDepartment of Genetics, Stanford University School of Medicine, Stanford, CA, USA.
Sijie LinDepartment of Genetics, Stanford University School of Medicine, Stanford, CA, USA.
Kaitlyn SpeesDepartment of Genetics, Stanford University School of Medicine, Stanford, CA, USA.
Christina CurtisDepartment of Genetics, Stanford University School of Medicine, Stanford, CA, USA.
Livnat Jerby-ArnonDepartment of Genetics, Stanford University School of Medicine, Stanford, CA, USA.ORCID http://orcid.org/0000-0002-4037-386X
Irving L WeissmanInstitute for Stem Cell Biology and Regenerative Medicine, Stanford University School of Medicine, Stanford, CA, USA.ORCID http://orcid.org/0000-0002-9077-7467
Julien SageDepartment of Genetics, Stanford University School of Medicine, Stanford, CA, USA.ORCID http://orcid.org/0000-0002-8928-9968
Michael C BassikDepartment of Genetics, Stanford University School of Medicine, Stanford, CA, USA. bassik@stanford.edu.ORCID http://orcid.org/0000-0001-5185-8427
Stanford University · USStanford Health Care · USChan Zuckerberg Initiative (United States) · US
Funding
Stem Cell Biology, Cancer Stem Cell Biology, and Cancer ImmunotherapyR35CA220434 · NCI · STANFORD UNIVERSITY · PI WEISSMAN, IRVING L. · 2017 to 2023
$6.7MInvestigating molecular and cellular mechanisms of SCLC development to identify novel therapeutic strategiesR35CA231997 · NCI · STANFORD UNIVERSITY · PI SAGE, JULIEN · 2019 to 2025
$6.2MNovel therapeutic approaches for enhancing anti-tumor immunity in SCLCU01CA213273 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI BYERS, LAUREN AVERETT, HEYMACH, JOHN V. · 2017 to 2021
$3.0MAccelerating drug development and repurposing using systematic genetic interactioDP2HD084069 · NICHD · STANFORD UNIVERSITY · PI BASSIK, MICHAEL C · 2014 to 2014
$2.4MProgrammed Cell Removal (PrCR) by Macrophages: recognition and phagocytosis of target cellsR01AI143889 · NIAID · STANFORD UNIVERSITY · PI WEISSMAN, IRVING L. · 2020 to 2024
$2.0MNCI NIH HHS R35 CA220434NCI NIH HHS R35 CA231997NCI NIH HHS U01 CA213273NIAID NIH HHS R01 AI143889NICHD NIH HHS DP2 HD084069
Abstract
Monoclonal antibody therapies targeting tumour antigens drive cancer cell elimination in large part by triggering macrophage phagocytosis of cancer cells
Indexed as
CRISPR-Cas SystemsAnimalsAntibodies, MonoclonalAntibody-Dependent Cell CytotoxicityAntigens, NeoplasmCD47 AntigenCell Line, TumorCells, CulturedCytophagocytosisFemaleGene EditingGene Knockout TechniquesHumansLymphoma, T-CellMacrophagesMaleAntibodies, MonoclonalAntigens, NeoplasmAPMAP protein, humanCD47 AntigenCD47 protein, humanGPR84 protein, humanMembrane GlycoproteinsReceptors, G-Protein-Coupled
Identifiers
What OpenQuestion holds
Textmetadata
LicenceTDM
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.